Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS. (From -To)
REPORT DATE (DD-MM-YYYY)
April 2006
REPORT TYPE
Annual Summary
DATES COVERED
SPONSOR/MONITOR'S REPORT NUMBER(S)
DISTRIBUTION / AVAILABILITY STATEMENTApproved for Public Release; Distribution Unlimited
SUPPLEMENTARY NOTES
ABSTRACTThe major goal of this project is to determine if the rhodacyanine analog dye, MKT-077, can be used to inhibit breast cancer cell oxygen metabolism and raise tumor oxygen levels, thereby radiosensitizing the tumor. In the first year, we have performed in vitro experiments to determine drug uptake and subsequent MKT-077-induced metabolic inhibition in human MDA-MB 231 cells, as outlined in Tasks 1 and 2. We originally proposed to do this work in our multicellular layer (MCL) model of tumor parenchyma, but we had difficulty growing MCLs from this cell line consistently. Therefore, we have begun determining MKT-077 drug uptake and metabolic inhibition using MDA-MB 231 monolayers and cell suspensions. This approach has been successful, and we have been able to show that the cells rapidly take up the drug, which inhibits cellular oxygen metabolism by 22% at a dose of 4 µg/ml. We are currently completing the drug uptake studies and determining the inhibition caused by other doses. In addition, we have begun the in vivo work in nude rats. We have determined that the rats can tolerate a dose of 10 mg/kg MKT-077 infused at 1.25 mg/kg/min. Soon we will begin measuring MKT-077-induced oxygen changes in orthotopic xenografts in vivo.15. Subject Terms (keywords previously assigned to proposal abstract or terms which apply to this award)